(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
This Huge Ocean Beast Shifts Sharks’ Evolutionary Timeline - 2Select Your Cherished Fish
- 3Defeating An inability to embrace success in Scholarly world: Individual Victories
- 4Saudi Arabia says it intercepted 7 missiles, debris falls near energy facilities
- 5Interstellar comet 3I/ATLAS reveals weird wobbling jets in rare sun-facing tail
- 5 Eating routine Well disposed Snacks to Keep You Fulfilled
- AstraZeneca to invest $2 billion as part of US manufacturing push
- Medtronic has 'significant firepower' for multiple acquisitions, executives say
- Olivia Rodrigo announces 3rd album, 'You Seem Pretty Sad for a Girl So in Love,' set to debut in June
- Fundamental Home Machines: An Easy to understand Determination Guide
- More than half way to the moon, the Artemis II astronauts are grappling with a toilet problem
- Promising Speculation Bearings for Portfolio Development in 2024
- Advocacy groups react after Mattel introduces 1st Barbie doll with autism
- Airbnb Unveils Airport Pickup Service Across 125 Cities in Global Expansion
